• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin.丙型肝炎患者自我报告的聚乙二醇干扰素和利巴韦林治疗依从性。
Aliment Pharmacol Ther. 2008 Aug 1;28(3):289-93. doi: 10.1111/j.1365-2036.2008.03718.x.
2
Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients.HIV/丙型肝炎病毒合并感染患者对丙型肝炎病毒治疗的依从性。
AIDS Behav. 2013 Jan;17(1):94-103. doi: 10.1007/s10461-012-0288-9.
3
Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.聚乙二醇化干扰素-α2a与利巴韦林诱导期对HIV-HCV合并感染患者早期病毒学应答的影响：CORAL-2研究结果
Antivir Ther. 2011;16(6):833-41. doi: 10.3851/IMP1837.
4
IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.IL28B 多态性、治疗前 CXCL10 和 HCV RNA 水平可预测不同种族的 HIV/HCV 合并感染和 HCV 单感染患者的治疗反应。
J Acquir Immune Defic Syndr. 2013 May 1;63(1):9-16. doi: 10.1097/QAI.0b013e31828323c1.
5
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.聚乙二醇干扰素和利巴韦林早期治疗HIV感染患者急性丙型肝炎感染的疗效。
AIDS. 2006 May 12;20(8):1157-61. doi: 10.1097/01.aids.0000226956.02719.fd.
6
Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.干扰素联合利巴韦林的持续病毒学应答可降低 HIV 和丙型肝炎病毒合并感染患者的非肝脏相关死亡率。
Clin Infect Dis. 2012 Sep;55(5):728-36. doi: 10.1093/cid/cis500. Epub 2012 May 18.
7
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.抗逆转录病毒疗法对丙型肝炎病毒/艾滋病病毒合并感染患者接受聚乙二醇干扰素加利巴韦林治疗后持续病毒学应答率的影响。
J Antimicrob Chemother. 2007 Dec;60(6):1347-54. doi: 10.1093/jac/dkm373. Epub 2007 Oct 14.
8
Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.综述文章：慢性丙型肝炎药物治疗的依从性——借鉴人类免疫缺陷病毒抗逆转录病毒治疗依从性研究的模式。
Aliment Pharmacol Ther. 2009 Jul;30(1):14-27. doi: 10.1111/j.1365-2036.2009.04004.x. Epub 2009 Mar 26.
9
IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.IL28B 基因多态性与聚乙二醇干扰素和利巴韦林治疗的 HIV/丙型肝炎病毒合并感染患者的病毒动力学。
AIDS. 2011 May 15;25(8):1025-33. doi: 10.1097/QAD.0b013e3283471cae.
10
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.针对丙型肝炎病毒2/3型感染的注射吸毒者，采用响应引导的聚乙二醇化干扰素和利巴韦林治疗的依从性：ACTIVATE研究。
BMC Infect Dis. 2017 Jun 13;17(1):420. doi: 10.1186/s12879-017-2517-3.

引用本文的文献

1
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.针对丙型肝炎病毒2/3型感染的注射吸毒者，采用响应引导的聚乙二醇化干扰素和利巴韦林治疗的依从性：ACTIVATE研究。
BMC Infect Dis. 2017 Jun 13;17(1):420. doi: 10.1186/s12879-017-2517-3.
2
New Therapies, Evidence, and Guidance in Hepatitis C Management: Expert Practices and Insights from an Educational Symposium at the AMCP 27th Annual Meeting Expo.丙型肝炎管理中的新疗法、证据和指导：在 AMCP 第 27 届年会博览会上的教育研讨会中的专家实践和见解。
J Manag Care Spec Pharm. 2015 Sep;21(9):S1-14. doi: 10.18553/jmcp.2015.21.9.S1.
3
Self-efficacy and adherence to antiviral treatment for chronic hepatitis C.慢性丙型肝炎的自我效能与抗病毒治疗依从性
J Clin Gastroenterol. 2015 Jan;49(1):76-83. doi: 10.1097/MCG.0000000000000055.
4
Impact of hepatitis C treatment initiation on adherence to concomitant medications.丙肝治疗起始对伴随用药依从性的影响。
J Assoc Nurses AIDS Care. 2014 Jan-Feb;25(1):23-31. doi: 10.1016/j.jana.2013.07.004. Epub 2013 Sep 24.
5
Adherence to chronic hepatitis C treatment regimen: first report from a referral center in iran.慢性丙型肝炎治疗方案的依从性：来自伊朗一家转诊中心的首份报告。
Hepat Mon. 2013 Jun 23;13(6):e11038. doi: 10.5812/hepatmon.11038. eCollection 2013.
6
Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence.慢性丙型肝炎聚乙二醇/利巴韦林治疗的依从性：漏服和非持续治疗的发生率、模式和预测因素。
J Viral Hepat. 2013 Aug;20(8):536-49. doi: 10.1111/jvh.12079. Epub 2013 Feb 25.
7
Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients.HIV/丙型肝炎病毒合并感染患者对丙型肝炎病毒治疗的依从性。
AIDS Behav. 2013 Jan;17(1):94-103. doi: 10.1007/s10461-012-0288-9.
8
Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?慢性丙型肝炎与抗病毒治疗方案：心理学能做出哪些贡献？
J Consult Clin Psychol. 2013 Apr;81(2):361-74. doi: 10.1037/a0029030. Epub 2012 Jun 25.
9
Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients.与HIV合并感染患者丙型肝炎病毒治疗依从性、治疗完成率和持续病毒学应答相关的患者特征
AIDS Res Treat. 2011;2011:903480. doi: 10.1155/2011/903480. Epub 2011 Oct 26.
10
Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study.慢性丙型肝炎病毒治疗依从性与病毒学应答的关系：一项队列研究。
Ann Intern Med. 2011 Sep 20;155(6):353-60. doi: 10.7326/0003-4819-155-6-201109200-00003.

本文引用的文献

1
Limited uptake of hepatitis C treatment among injection drug users.注射吸毒者中丙型肝炎治疗的接受率有限。
J Community Health. 2008 Jun;33(3):126-33. doi: 10.1007/s10900-007-9083-3.
2
HIV and liver disease forum: conference proceedings.艾滋病病毒与肝脏疾病论坛：会议论文集
Hepatology. 2007 Jun;45(6):1566-77. doi: 10.1002/hep.21722.
3
Assessing the validity of self-reported medication adherence in hepatitis C treatment.评估丙型肝炎治疗中自我报告的药物依从性的有效性。
Ann Pharmacother. 2007 Jul;41(7):1116-23. doi: 10.1345/aph.1K024. Epub 2007 May 22.
4
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.艾滋病毒和丙型肝炎病毒合并感染患者的护理：HCV-HIV国际小组2007年更新建议
AIDS. 2007 May 31;21(9):1073-89. doi: 10.1097/QAD.0b013e3281084e4d.
5
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.慢性丙型肝炎患者再治疗期间降低聚乙二醇干扰素α-2a和利巴韦林剂量的影响
Gastroenterology. 2007 Jan;132(1):103-12. doi: 10.1053/j.gastro.2006.11.011. Epub 2006 Nov 11.
6
Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.聚乙二醇化干扰素类型对HIV-HCV合并感染患者抑郁及神经精神症状发作的影响。
AIDS Care. 2007 Jan;19(1):138-45. doi: 10.1080/09540120600645539.
7
Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care.人类免疫缺陷病毒和丙型肝炎病毒合并感染患者的治疗挑战：团队护理的必要性。
Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S349-54. doi: 10.1086/427452.
8
Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin.HIV感染患者中的慢性丙型肝炎：聚乙二醇化干扰素α联合利巴韦林治疗的低入选率和适用性
J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):238-40. doi: 10.1097/01.qai.0000148535.97081.72.
9
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.聚乙二醇化干扰素α-2b与标准干扰素α-2b联合利巴韦林治疗HIV感染患者慢性丙型肝炎的随机对照试验。
JAMA. 2004 Dec 15;292(23):2839-48. doi: 10.1001/jama.292.23.2839.
10
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.聚乙二醇干扰素α-2a联合利巴韦林与干扰素α-2a联合利巴韦林治疗合并感染HIV的慢性丙型肝炎患者的疗效比较
N Engl J Med. 2004 Jul 29;351(5):451-9. doi: 10.1056/NEJMoa032653.

丙型肝炎患者自我报告的聚乙二醇干扰素和利巴韦林治疗依从性。

Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin.

作者信息

Weiss J J, Bhatti L, Dieterich D T, Edlin B R, Fishbein D A, Goetz M B, Yu K, Wagner G J

机构信息

Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA.

出版信息

Aliment Pharmacol Ther. 2008 Aug 1;28(3):289-93. doi: 10.1111/j.1365-2036.2008.03718.x.

DOI:10.1111/j.1365-2036.2008.03718.x
PMID:19086329
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2891196/
Abstract

BACKGROUND

Prior research on adherence to hepatitis C treatment has documented rates of dose reductions and early treatment discontinuation, but little is known about patients' dose-taking adherence.

AIMS

To assess the prevalence of missed doses of pegylated interferon and ribavirin and examine the correlates of dose-taking adherence in clinic settings.

METHODS

One hundred and eighty patients on treatment for hepatitis C (23% coinfected with HIV) completed a cross-sectional survey at the site of their hepatitis C care.

RESULTS

Seven per cent of patients reported missing at least one injection of pegylated interferon in the last 4 weeks and 21% reported missing at least one dose of ribavirin in the last 7 days. Dose-taking adherence was not associated with HCV viral load.

CONCLUSIONS

Self-reported dose non-adherence to hepatitis C treatment occurs frequently. Further studies of dose non-adherence (assessed by method other than self-report) and its relationship to HCV virological outcome are warranted.

摘要

背景

先前关于丙型肝炎治疗依从性的研究记录了剂量减少和早期治疗中断的发生率，但对于患者的服药依从性知之甚少。

目的

评估聚乙二醇干扰素和利巴韦林漏服剂量的发生率，并在临床环境中检查服药依从性的相关因素。

方法

180例接受丙型肝炎治疗的患者（23%合并感染HIV）在其丙型肝炎治疗地点完成了一项横断面调查。

结果

7%的患者报告在过去4周内至少漏打了一针聚乙二醇干扰素，21%的患者报告在过去7天内至少漏服了一剂利巴韦林。服药依从性与丙型肝炎病毒载量无关。

结论

自我报告的丙型肝炎治疗剂量不依从情况频繁发生。有必要进一步研究剂量不依从（通过自我报告以外的方法评估）及其与丙型肝炎病毒学结果的关系。